ReviewClinical microbiology reviews2013
β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula.
Review in Clinical microbiology reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 175 citations in OpenAlex.
- Nurse-Led and Nurse-Involved Antimicrobial Stewardship in Hospitals and Primary Care: Protocol for a Mixed Methods Systematic Review and Meta-Analysis With Gulf Cooperation Council and Middle East and North Africa Subgroup Analysis.JMIR research protocols · 2026Article
- Risk factors associated with carbapenem-resistant Gram-negative bacterial infections in intensive care units in Jordan.BMC infectious diseases · 2026Article
- Antimicrobial resistance patterns of Klebsiella pneumoniae clinical isolates in the Qassim region, Saudi Arabia: a surveillance study (2015-2023).BMC infectious diseases · 2026Article
- Antimicrobial Resistance Trends in Carbapenem-Resistant Enterobacterales in a Saudi Healthcare Setting.Microorganisms · 2026Article
- Difficult-to-treat resistance, not carbapenem non-susceptibility, is associated with 30-day mortality in respiratory gram-negative bacilli: a 12-year surveillance cohort.Frontiers in cellular and infection microbiology · 2026Article
- Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020-2024.Frontiers in cellular and infection microbiology · 2026Article
- Characteristics and outcomes of patients treated with tigecycline for MDR gram-negative infections: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Whole-genome sequencing-based characterization of resistome and virulome inFrontiers in microbiology · 2026Article
- Class-matched antibiotic dispensing and susceptibility transitions in recurrent urinary gram-negative bacilli.Frontiers in cellular and infection microbiology · 2026Article
- Gut microbiome dysbiosis and antimicrobial resistance in the Middle East: a converging public health crisis in conflict and fragile settings.Archives of microbiology · 2025Review
- First national study on genomic profiling ofEnvironmental challenges (Amsterdam, Netherlands) · 2025Article
- Efficacy of imipenem combined with dimercaptosuccinic acid in a murine sepsis model using Pseudomonas aeruginosa.Scientific reports · 2025Article
- Prevalence and Antibiogram Pattern ofAntibiotics (Basel, Switzerland) · 2025Article
- Clinical characteristics and outcomes of liver abscesses: a 12-year retrospective analysis from a tertiary care center in the United Arab Emirates.Frontiers in medicine · 2025Article
- Hospital acquired infections in Intensive Care Unit: A study on incidence, antibiotic resistance profile and outcome of the patients in a tertiary care unit in Eastern India.AIMS microbiology · 2025Article
- Epidemiological and genetic characteristics of clinical carbapenemase-producing Enterobacterales isolates from Batna hospitals in Algeria.BMC infectious diseases · 2024Article
- Development of a Multiplex PCR Assay for the Detection of Extended-Spectrum Beta-Lactamase Genes inIndian journal of microbiology · 2024Article
- Clinical, phenotypic, and genotypic characteristics of ESBL-producingIJID regions · 2024Article
- Phenotypic and Genotypic Characterization of Pan-Drug-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Genomic diversity of β-lactamase producing Pseudomonas aeruginosa in Iran; the impact of global high-risk clones.Annals of clinical microbiology and antimicrobials · 2024Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
SUMMARY Infections due to Gram-negative bacilli (GNB) are a leading cause of morbidity and mortality worldwide. The extent of antibiotic resistance in GNB in countries of the Gulf Cooperation Council (GCC), namely, Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, and Bahrain, has not been previously reviewed. These countries share a high prevalence of extended-spectrum-β-lactamase (ESBL)- and carbapenemase-producing GNB, most of which are associated with nosocomial infections. Well-known and widespread β-lactamases genes (such as those for CTX-M-15, OXA-48, and NDM-1) have found their way into isolates from the GCC states. However, less common and unique enzymes have also been identified. These include PER-7, GES-11, and PME-1. Several potential risk factors unique to the GCC states may have contributed to the emergence and spread of β-lactamases, including the unnecessary use of antibiotics and the large population of migrant workers, particularly from the Indian subcontinent. It is clear that active surveillance of antimicrobial resistance in the GCC states is urgently needed to address regional interventions that can contain the antimicrobial resistance issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.